Using Biolosion with standard therapy to treat triple-negative breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the efficacy and safety of Biolosion, an oral probiotic compound, when combined with standard neoadjuvant therapy for women diagnosed with locally advanced triple-negative breast cancer. Participants will be assessed for eligibility based on specific criteria, including tumor characteristics and overall health status. The trial aims to determine if this combination can improve treatment outcomes for patients with this aggressive form of breast cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Women aged 1.18 years and above, diagnosed with triple-negative breast cancer (ER≤10%, PR≤10%, HER-2 negative) by pathology;
2. Patients must have tumor specimens (formalin-fixed, paraffin-embedded, or fresh pre-treated tumor tissue) available for PD-L1 expression testing;
3. Researchers assess indications for neoadjuvant chemotherapy, with staging from IIA to IIIC, based on imaging or pathological evaluation of cT1c, N1-3, or cT2\~cT4, cN0\~N3, and patients with no distant metastasis as evaluated by imaging;
4. Patients must not have received chemotherapy or targeted therapy for advanced breast cancer;
5. ECOG PS: 0-2;
6. Expected survival of ≥12 weeks;
7. Major organ function levels must meet the following criteria:

1\) Hematological examination standards must meet: ANC≥1.5×10\^9/L, PLT≥75×10\^9/L, Hb≥90g/L (no blood transfusions or blood products within 14 days, and no use of G-CSF or other hematopoietic growth factors for correction) 2) Biochemical examination must meet the following standards: TBIL\<1.5×ULN, ALT, AST\<2.5×ULN, for patients with liver metastasis, ALT, AST may be \<5×ULN, BUN and Cr≤1×ULN or endogenous creatinine clearance ≥50ml/min (Cockcroft-Gault formula); 8. Women of childbearing age must have taken reliable contraceptive measures or undergone a pregnancy test (serum or urine) within 7 days prior to enrollment, with a negative result, and must be willing to use appropriate contraceptive methods during the trial and for 8 weeks after the last administration of the investigational drug.

9\. Participants voluntarily join this study, demonstrate good compliance, and cooperate with follow-up.

Exclusion Criteria:

1. There is a clear distant transfer;
2. A history of autoimmune diseases;
3. Acute or chronic active hepatitis B (defined as positive hepatitis B surface antigen and/or hepatitis B core antibody, with hepatitis B virus DNA copy number ≥1×10³ copies/ml or ≥200 IU/ml) or positive antibodies for acute or chronic active hepatitis C, with positive hepatitis C antibodies but negative RNA testing allowed for enrollment.
4. Previous treatment with immune checkpoint inhibitors;
5. Received systemic immunostimulants, systemic corticosteroids, or immunosuppressants within the last 4 weeks;
6. Any severe underlying disease, comorbidities, and active infections, or patients with severe metabolic disorders;
7. Currently receiving other antitumor treatments;
8. Known comorbidities (e.g., chronic diarrhea, inflammatory bowel disease, etc.) that, in the investigator's assessment, would increase the risk associated with the administration of the study drug or interfere with the interpretation of study results.
9. Currently using or planning to use probiotics, yogurt, or bacterial-enhanced foods during the treatment period.
10. A history of epilepsy or seizure-inducing states;
11. Pregnant or breastfeeding patients;
12. Poor compliance or inability to undergo normal follow-up;
13. Individuals allergic to the study drug;
14. Diagnosis of other malignancies within the past 5 years, with the exception of: surgically removed non-melanoma skin cancer, adequately treated cervical carcinoma in situ, locally curative prostate cancer, surgically treated ductal carcinoma in situ, or malignancies diagnosed 2 years prior to randomization without evidence of disease and untreated for ≤2 years;
15. The investigator's judgment on other conditions that may affect the conduct of the clinical study and the determination of study results.

Where it's running

• Sun yat sen university cancer center
  Guangzhou, Guangdong, China Recruiting
• Gansu Cancer Hospital
  Lanzhou, Gansu, China Not yet recruiting
• Dongguan People's Hospital
  Dongguan, Guangdong, China Not yet recruiting
• Central Hospital of Guangdong Nongken
  Zhanjiang, Guangdong, China Not yet recruiting
• Zigong Fourth People's hospital
  Zigong, Sichuan, China Not yet recruiting

Study contacts

• Study coordinator: Meiting Chen, Doctor
• Email: chenmt@sysucc.org.cn
• Phone: 020-87343368

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Precision neoadjuvant therapy for operable breast cancer

  This study is testing if a personalized treatment approach using new drugs for operable breast cancer can work better than standard chemotherapy alone.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT05582499

• Preoperative chemotherapy with pembrolizumab and a low or high radiation boost for node-positive triple-negative breast cancer

  This study tests whether giving a low or high radiation boost together with preoperative chemotherapy and pembrolizumab can better activate the immune system in people with node‑positive triple‑negative breast cancer.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07276880

• VSV-02 for advanced solid tumors

  This treatment will try VSV-02 given into a vein and directly into tumors to see if it helps people with advanced solid tumors who have limited treatment options.

  Recruiting Phase 1 The First Affiliated Hospital of Xinxiang Medical College · Xinxiang, Henan · NCT07260591

• Using blood-based tumor DNA (ctDNA) to find leftover breast cancer after treatment

  This research will test whether a simple blood test that looks for tiny bits of tumor DNA can tell if people treated for breast cancer (including HR+/HER2-, HER2+, and triple-negative) still have leftover cancer or are at risk of recurrence.

  Recruiting at 16 sites Tempus AI · Birmingham, Alabama and 15 other locations · NCT07211178

• Switching aromatase inhibitors versus guideline-based side-effect care to help with AI side effects

  This test tries switching one aromatase inhibitor to another versus using guideline-based side-effect care to see which helps postmenopausal women with early-stage ER-positive breast cancer stay on their hormone therapy.

  Recruiting Phase 2 Dartmouth-Hitchcock Medical Center · Lebanon, New Hampshire · NCT07071038

• ctDNA surveillance with Dato-DXd for people with high-risk early triple-negative breast cancer and residual disease

  This study will test whether regular blood-based ctDNA monitoring can find tiny relapses in adults with stage II/III triple-negative breast cancer who have residual disease after neoadjuvant therapy and whether early treatment with Dato-DXd when ctDNA becomes positive can reduce recurrence.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07069595

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.